首页 > 市场调查报告书 > 製药

感染疾病

大环内酯类抗生素市场规模、份额及成长分析（依药物、给药途径、适应症、最终用户及地区划分）－产业预测，2026-2033年

市场调查报告书

商品编码

1902325

大环内酯类抗生素市场规模、份额及成长分析（依药物、给药途径、适应症、最终用户及地区划分）－产业预测，2026-2033年

Macrolide Antibiotics Market Size, Share, and Growth Analysis, By Drugs (Azithromycin, Clarithromycin), By Administration (Oral, Parenteral), By Indication, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 218 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球大环内酯类抗生素市场规模将达到 59.3 亿美元，到 2025 年将成长至 60.7 亿美元，到 2033 年将成长至 72.8 亿美元，预测期（2026-2033 年）的复合年增长率为 2.3%。

全球大环内酯类抗生素市场受感染疾病（尤其是呼吸道疾病和性行为感染感染疾病）日益普遍的推动。大环内酯类抗生素的特点是具有大环内酯结构，能够抑制细菌蛋白质合成。它们通常表现出抑菌活性，但在高剂量下可表现出杀菌活性。它们广泛用于治疗肺炎、支气管炎、沙眼衣原体感染和淋病等疾病。社区型肺炎发生率的上升，特别是由于人口结构变化，正在推动对这类抗生素的需求。此外，非专利大环内酯类抗生素的日益普及也促进了市场扩张，因为相关人员致力于开发现有品牌产品的成本效益更高的替代品。这一趋势支持了大环内酯类抗生素市场份额扩张的战略潜力。

全球大环内酯类抗生素市场驱动因素

全球大环内酯类抗生素市场预计将迎来显着成长，尤其是在中国、印度和巴西等新兴经济体。这些地区人口众多，医疗保健成本不断攀升，导致对高效抗生素的需求日益增长。此外，这些市场细菌感染疾病的日益普遍也为生产商提供了拓展业务、满足市场对高效治疗方案日益增长的需求的广泛机会。随着医疗基础设施的不断完善，大环内酯类抗生素市场有望受益于人们对健康问题的日益关注以及有效对抗感染疾病的迫切需求。

限制全球大环内酯类抗生素市场的因素

由于抗生素抗药性微生物的日益增多，全球大环内酯类抗生素市场面临严峻挑战。这种抗药性，尤其是对大环内酯类抗生素的抗药性，主要是由于这些药物的过度使用和不合理使用所造成的。随着抗生素抗药性的不断增强，大环内酯类抗生素作为细菌感染疾病有效治疗方法的长期疗效可能会下降。为了应对这一令人担忧的趋势，必须开发创新药物和替代治疗策略，以有效对抗抗生素抗药性细菌，并确保其在治疗感染疾病的持续有效性。

全球大环内酯类抗生素市场趋势

由于迫切需要应对日益严重的细菌抗药性并提高治疗效果，全球大环内酯类抗生素市场目前正经历显着成长。这一趋势的特点是研发投入不断增加，致力于开发新型大环内酯衍生物和具有更佳药物动力学和更广治疗范围的创新製剂。製药公司正优先开发先进的大环内酯类抗生素，以应对不断演变的微生物威胁并优化现有多种疾病的治疗方法。这种积极进取的策略体现了製药公司确保在对抗细菌感染疾病安全有效，并最终塑造大环内酯类抗生素市场未来的决心。

Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
AbbVie Inc.（USA）
Sanofi SA（France）
Novartis AG（Switzerland）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Mylan NV（USA）
Daiichi Sankyo Company, Limited（Japan）
Sun Pharmaceutical Industries Limited（India）
Cipla Limited（India）
Lupin Limited（India）
Zydus Lifesciences Limited（India）
Alkem Laboratories Ltd.（India）
Zhejiang Guobang Pharmaceutical Co., Ltd.（China）
Bristol Myers Squibb（USA）
Abbott Laboratories（USA）
Eli Lilly and Company（USA）
Amgen Inc.（USA）
Sandoz International GmbH（Germany）

结论与建议

简介目录

Product Code: SQMIG35I2327

Global Macrolide Antibiotics Market size was valued at USD 5.93 Billion in 2024 and is poised to grow from USD 6.07 Billion in 2025 to USD 7.28 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global market for macrolide antibiotics is being driven by an increase in infectious disease prevalence, particularly respiratory and sexually transmitted infections. Characterized by their macrocyclic lactone structure and ability to inhibit bacterial protein synthesis, macrolides, while typically bacteriostatic, can exhibit bactericidal effects at higher doses. They are widely utilized to treat conditions such as pneumonia, bronchitis, chlamydia, and gonorrhea. The rising incidence of community-acquired pneumonia, notably influenced by demographics, enhances the demand for these antibiotics. Additionally, the growing accessibility of generic macrolide options contributes to market expansion, as stakeholders focus on developing cost-effective alternatives to established brand-name products. This trend underscores the strategic potential for increased market share in the macrolide antibiotics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segments Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is poised for significant growth, particularly in emerging economies such as China, India, and Brazil. These regions, characterized by large populations and escalating healthcare expenses, demonstrate a heightened demand for effective antibiotics. Moreover, the increasing prevalence of bacterial infections in these markets creates ample opportunities for manufacturers to expand their presence and tap into the growing need for efficient treatment solutions. As healthcare infrastructure continues to develop, the macrolide antibiotics sector stands to benefit from the rising awareness of health issues and the urgency to address infectious diseases effectively.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant challenges due to the increasing prevalence of microorganisms that have developed resistance to antibiotics. This resistance, especially to macrolides, stems largely from the overuse and inappropriate use of these medications. As antibiotic resistance rises, the long-term viability of macrolide antibiotics as effective treatments for bacterial infections may diminish. Addressing this concerning trend necessitates the development of innovative drugs and alternative therapeutic strategies to effectively combat antibiotic-resistant bacteria and ensure continued efficacy in treating infections.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is currently experiencing significant growth, driven by the urgent need to combat rising bacterial resistance and enhance treatment efficacy. This trend is characterized by increased research and development efforts aimed at creating novel macrolide derivatives and innovative formulations that improve pharmacokinetics and broaden their therapeutic range. Pharmaceutical companies are prioritizing the development of advanced macrolide antibiotics to address evolving microbial threats and optimize existing treatments for diverse illnesses. This proactive approach reflects a commitment to ensuring safety and effectiveness in combating bacterial infections, ultimately shaping the future landscape of the macrolide antibiotic market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2026-2033)

Market Overview
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2026-2033)

Market Overview
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Dermatology clinics
Pharmaceutical companies
Others

Global Macrolide Antibiotics Market Size & CAGR (2026-2033)

North America (Drugs, Administration, Indication, End User)
- US
- Canada
Europe (Drugs, Administration, Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drugs, Administration, Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drugs, Administration, Indication, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drugs, Administration, Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkem Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments